2011～2013年我院NICU革兰阴性杆菌耐药性分析  

Drug resistance of Gram-negative Bacilli in patients in NICU from 2011 to 2013

作　　者：田君[1] 朱秀梅[1] 李琦[1] 池丽燕[1] 魏梁锋[1] 郑兆聪[1] 王守森[1] 

机构地区：[1]南京军区福州总医院神经外科,福州350025

出　　处：《中国临床神经外科杂志》2016年第7期422-424,共3页Chinese Journal of Clinical Neurosurgery

摘　　要：目的总结分析近3年我院神经外科重症监护病房(NICU)患者的标本革兰阴性杆菌耐药性变化趋势,以指导临床合理使用抗菌药物。方法分析2011年1月至2013年12月NICU内患者的标本中分离出革兰阴性杆菌,采用最低抑菌浓度法对所检出细菌进行药敏检测,并用WHONET 5.3软件进行数据分析。结果共检出363株革兰阴性杆菌,占前3位的为不动杆菌属(34.7%)、铜绿假单胞菌(24.5%)及肺炎克雷伯菌(20.4%);不动杆菌属对阿米卡星和头孢哌酮/舒巴坦的耐药率最低,分别为4.0%和15.9%。铜绿假单胞菌对哌拉西林/他唑巴坦耐药性约33.3%。肺炎克雷伯菌除了对碳青霉烯类耐药性降低外,对其他抗菌素耐药性有增多趋势。结论在NICU革兰阴性杆菌中,亚胺培南、头孢哌酮/舒巴坦与哌拉西林/他唑巴坦对革兰阴性杆菌具有很好的敏感性。Objective To study the drug resistance of Gram-negative bacilli in the patients in neurosurgery intensive care unit （NICU） in order to provide guidance for the rational use of antibiotics. Method From January, 2011 to December, 2013, the antimicrobial susceptibility test was performed in the Gram-negative bacilli isolated from the patients in NICU by minimum inhibitory concentration method. The results were analyzed by WHONET 5.3 Software. Results The first three pathogens of 363 strains were Aeinetobacter spp （34.7%）, Pseudomonas aeruginosa （24.5%） and Klebsiella pneumonia （20.4%） respectively. The resistance rate of Aeinetobaeter spp to amikacin and cefoperazone-sulbactam were 4.0% and 15.9% respectively. The resistance rate of pseudomonas aeruginosa to piperacillin-tazobactam was about 33.3%. Conclusions In NICU, imipenem cefoperazone-sulbactam and piperacillin-tazobactam remain high activity against Gram-negative bacilli in NICU.

关 键 词：神经外科重症监护病房 革兰阴性杆菌 耐药性 

分 类 号：R651[医药卫生—外科学] R446.5[医药卫生—临床医学]